San Mateo, Ca., USA - February 4, 2010, San Mateo, Ca., USA - NeurogesX, a biopharmaceutical company, announced that three management team members have received promotions.
Article continues below
The following exectuive were promoted: Stephen Ghiglieri has been named Executive Vice President, Chief Operating Officer and Chief Financial Officer. He was previously Chief Financial Officer. Jeffrey Tobias, M.D. has been promoted to Executive Vice President Research and Development and Chief Medical Officer. He was previously Chief Medical Officer. Michael Markels has been appointed Senior Vice President, Commercial and Business Development. He was previously Vice President, Commercial Operations and Business Development.
Mr. Ghiglieri has served as Chief Financial Officer of NeurogesX since October 2003. Mr. Ghiglieri is a Certified Public Accountant with over 25 years experience in corporate finance and accounting. Previously, Mr. Ghiglieri served on the management teams of Hansen Medical, Inc.; Avolent, Inc.; Andromedia, Inc.; and Oacis Healthcare Systems.
Mr. Ghiglieri has also served as Controller of Oclassen Pharmaceuticals, Inc. From 1984 to 1992, he served as an audit manager of PricewaterhouseCoopers, LLP. Mr. Ghiglieri received a B.A. in business administration from California State University, Hayward.
Mr. Tobias, M.D. joined NeurogesX as Chief Medical Officer in November 2005. Dr. Tobias brings more than 18 years experience in domestic and international clinical drug development, regulatory submissions and strategic planning. From September 1996 to November 2005, Dr. Tobias served as owner and principal of the Aquila Consulting Group.
Previously, Dr. Tobias held positions in clinical research and development at Alza Corporation, Chiron Corporation, and Xoma Corporation. Dr. Tobias received board-certification in both Internal Medicine and Pulmonary Medicine and completed training in Critical Care Medicine at the University of California, Los Angeles. Mr. Tobias received his bachelor's degree and medical degree with honors from the University of Illinois.
Mr. Markels joined NeurogesX in May 2006, initially as Vice President, Commercial Operations and Business Development. He has 18 years experience in domestic and international sales, strategic marketing and drug development. Previously, Mr. Markels had senior sales and marketing responsibilities for Rituxan at Biogen Idec and the Infectious Disease Business Unit at InterMune. ■